Literature DB >> 25595571

Autoimmune liver disease in Noonan Syndrome.

Italia Loddo1, Claudio Romano2, Maria Concetta Cutrupi3, Marco Sciveres4, Silvia Riva5, Annamaria Salpietro6, Valeria Ferraù7, Romina Gallizzi8, Silvana Briuglia9.   

Abstract

Noonan Syndrome (NS) is characterized by short stature, typical facial dysmorphology and congenital heart defects. The incidence of NS is estimated to be between 1:1000 and 1:2500 live births. The syndrome is transmitted as an autosomal dominant trait. In approximately 50% of cases, the disease is caused by missense mutations in the PTPN11 gene on chromosome 12, resulting in a gain of function of the non-receptor protein tyrosine phosphatase SHP-2 protein. Autoimmune Hepatitis (AIH) is a cryptogenic, chronic and progressive necroinflammatory liver disease. Common features of AIH are hypergammaglobulinemia (IgG), presence of circulating autoantibodies, histological picture of interface hepatitis and response to immunosuppressant drugs. Conventional treatment with Prednisone and Azathioprine is effective in most patients. We describe the case of a 6 years-old girl with Noonan Syndrome and Autoimmune Hepatitis type 1. Molecular analysis of PTPN11 gene showed heterozygous mutation c.923A>G (Asn308Ser) in exon 8. Though association between NS and autoimmune disorders is known, this is the second case of association between Noonan Syndrome and Autoimmune Hepatitis type 1 described in literature. In the management of NS, an accurate clinical evaluation would be recommended. When there is a clinical suspicion of autoimmune phenomena, appropriate laboratory tests should be performed with the aim of clarifying whether the immune system is involved in NS. We think that autoimmunity represents a characteristic of NS, even if the etiopathogenesis is still unknown.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Autoimmune hepatitis; Noonan syndrome; PTPN11; RASopathies

Mesh:

Substances:

Year:  2015        PMID: 25595571     DOI: 10.1016/j.ejmg.2014.12.013

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  3 in total

Review 1.  Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.

Authors:  Jie Pan; Lisha Zhou; Chenyang Zhang; Qiang Xu; Yang Sun
Journal:  Signal Transduct Target Ther       Date:  2022-06-04

2.  Intramolecular Interaction with the E6 Region Stabilizes the Closed Conformation of the N-SH2 Domain and Concurs with the Self-Inhibitory Docking in Downregulating the Activity of the SHP2 Tyrosine Phosphatase: A Molecular Dynamics Study.

Authors:  Emanuele Bellacchio
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

3.  DRESS syndrome with thrombotic microangiopathy revealing a Noonan syndrome: Case report.

Authors:  Mickaël Bobot; Matteo Coen; Clémentine Simon; Laurent Daniel; Gilbert Habib; Jacques Serratrice
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.